Literature DB >> 28314959

Cancer of unknown primary (CUP) of the head and neck: retrospective analysis of 81 patients.

Basel Al Kadah1, Giorgos Papaspyrou2, Maximilian Linxweiler2, Bernhard Schick2, Christian Rübe3, Benjamin Simeon Büchler3, Marcus Niewald3.   

Abstract

The treatment of patients with cervical lymph node metastases without detectable primary tumor remains an important challenge, until today, no standard therapy is available. The present study investigated the multimodal treatment of patients with head and neck CUP syndrome (HNCUP) and their follow-up retrospectively. 81 patients with cervical lymph node metastases without a primary tumor were treated at the Departments of Otorhinolaryngology as well as Radiotherapy and Radiation Oncology at the University of Saarland in Homburg, Germany in the period between 1991 and 2013. All patients received routine work-up consisting of CUP panendoscopy and imaging. Neck dissection was then performed in 77% of the patients. The most common histology was squamous cell carcinoma (80%). Ten percent of the patients had distant metastases. All patients underwent primary or adjuvant radiation therapy, or simultaneous radiochemotherapy. After a median follow-up of 3.5 years, the 5-year survival rate was 30%. There was a local recurrence that was known in 20/63 patients (31%) and distant metastases were documented in 19/61 M0 patients (31%). Higher grade late toxicity (grade 3-4) was observed in 12% of patients. Neck dissection and radiation therapy remains an integral part of HNCUP therapy, while the use of chemotherapy could be considered in selected cases. Prospective multicenter randomized trials would be necessary to identify the best target volume and to clarify the role of chemotherapy.

Entities:  

Keywords:  CUP; Cervical lymph nodes; Chemotherapy; Neck dissection; Radiation therapy

Mesh:

Substances:

Year:  2017        PMID: 28314959     DOI: 10.1007/s00405-017-4525-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  30 in total

1.  Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery.

Authors:  K Thomas Robbins; Garry Clayman; Paul A Levine; Jesus Medina; Roy Sessions; Ashok Shaha; Peter Som; Gregory T Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-07

2.  Radiotherapeutic management of cervical lymph node metastases from an unknown primary site.

Authors:  Stephanie M Perkins; Christopher R Spencer; Rebecca D Chernock; Bruce H Haughey; Brian Nussenbaum; Douglas R Adkins; David I Kuperman; Wade L Thorstad
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-07

3.  Diagnosis and management of carcinoma of unknown primary in the head and neck.

Authors:  Wolfgang J Issing; Behsad Taleban; Stefan Tauber
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-04-09       Impact factor: 2.503

4.  Metastatic squamous cell carcinoma in cervical lymph nodes from an unknown primary tumour: prognostic factors.

Authors:  J A Fernández; C Suárez; J A Martínez; J L Llorente; J P Rodrigo; J C Alvarez
Journal:  Clin Otolaryngol Allied Sci       Date:  1998-04

Review 5.  Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches.

Authors:  Primož Strojan; Alfio Ferlito; Jesus E Medina; Julia A Woolgar; Alessandra Rinaldo; K Thomas Robbins; Johannes J Fagan; William M Mendenhall; Vinidh Paleri; Carl E Silver; Kerry D Olsen; June Corry; Carlos Suárez; Juan P Rodrigo; Johannes A Langendijk; Kenneth O Devaney; Luiz P Kowalski; Dana M Hartl; Missak Haigentz; Jochen A Werner; Phillip K Pellitteri; Remco de Bree; Gregory T Wolf; Robert P Takes; Eric M Genden; Michael L Hinni; Vanni Mondin; Ashok R Shaha; Leon Barnes
Journal:  Head Neck       Date:  2011-10-27       Impact factor: 3.147

6.  Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head-and-neck mucosal site treated with radiation therapy alone or in combination with neck dissection.

Authors:  H S Erkal; W M Mendenhall; R J Amdur; D B Villaret; S P Stringer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-05-01       Impact factor: 7.038

Review 7.  Neck lymph node metastases from an unknown primary tumor retrospective study and review of literature.

Authors:  Hans Christiansen; Robert Michael Hermann; Alexios Martin; Mirko Nitsche; Heinz Schmidberger; Olivier Pradier
Journal:  Strahlenther Onkol       Date:  2005-06       Impact factor: 3.621

Review 8.  Cancer of unknown primary site.

Authors:  Nicholas Pavlidis; George Pentheroudakis
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

9.  Role of radiotherapy in the treatment of cervical lymph node metastases from an unknown primary site: retrospective analysis of 113 patients.

Authors:  Debora Beldì; Barbara A Jereczek-Fossa; Alberto D'Onofrio; Giuseppina Gambaro; Maria Rosaria Fiore; Francesco Pia; Fausto Chiesa; Roberto Orecchia; Marco Krengli
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-22       Impact factor: 7.038

10.  The occult head and neck primary: to treat or not to treat?

Authors:  K Sinnathamby; L J Peters; C Laidlaw; P G Hughes
Journal:  Clin Oncol (R Coll Radiol)       Date:  1997       Impact factor: 4.126

View more
  8 in total

1.  Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival.

Authors:  Miloslav Pala; Pavla Novakova; Zdena Pechacova; Lucie Vesela; Antonin Vrana; Jarmila Sukova; Petra Holeckova; Tereza Drbohlavova; Tomas Podlesak; Lubos Petruzelka
Journal:  Strahlenther Onkol       Date:  2022-08-09       Impact factor: 4.033

2.  The impact of the patient's condition, diagnostic procedures and treatment on the survival of carcinoma of unknown primary site patients.

Authors:  Karolina Dorobisz; Iwona Wlodarska-Polinska; Katarzyna Pazdro-Zastawny; Tomasz Rutkowski; Piotr Palka; Tomasz Dworzecki; Tomasz Zatonski
Journal:  Cancer Manag Res       Date:  2019-07-16       Impact factor: 3.989

3.  Treatment of head and neck carcinoma of unknown primary: Cracking a nut with a sledgehammer?

Authors:  Diako Berzenji; Dominiek A Monserez; Gerda M Verduijn; Emilie A C Dronkers; Peter P Jansen; Stijn Keereweer; Aniel Sewnaik; Robert J Baatenburg de Jong; Jose A Hardillo
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-03-26

Review 4.  A Systematic Review of Cancer of Unknown Primary in the Head and Neck Region.

Authors:  Milosz Pinkiewicz; Karolina Dorobisz; Tomasz Zatoński
Journal:  Cancer Manag Res       Date:  2021-09-18       Impact factor: 3.989

5.  Significance of the Neutrophil-to-Lymphocyte Ratio in p16-Negative Squamous Cell Carcinoma of Unknown Primary in Head and Neck.

Authors:  Chunmiao Xu; Junhui Yuan; Wei Du; Junfu Wu; Qigen Fang; Xu Zhang; Hailiang Li
Journal:  Front Oncol       Date:  2020-01-29       Impact factor: 6.244

6.  Radiotherapeutic management of cervical lymph node metastases from an unknown primary site - experiences from a large cohort treated with modern radiation techniques.

Authors:  Tanja Sprave; Alexander Rühle; Katharina Hees; Tobias Kalckreuth; Vivek Verma; Raluca Stoian; Constantinos Zamboglou; Jens Pfeiffer; Roland Laszig; Andreas Knopf; Anca-Ligia Grosu; Nils H Nicolay
Journal:  Radiat Oncol       Date:  2020-04-15       Impact factor: 3.481

7.  Failure patterns of cervical lymph nodes in metastases of unknown origin according to target volume.

Authors:  Dong-Yun Kim; Dae Seog Heo; Bhumsuk Keam; Chan Young Ock; Soon Hyun Ahn; Ji-Hoon Kim; Kyeong Cheon Jung; Jin Ho Kim; Hong-Gyun Wu
Journal:  Radiat Oncol J       Date:  2020-03-30

8.  Role of Tonsillectomy in the Management of Carcinomas of Unknown Primary of the Head and Neck: A Retrospective Study Based on p16 Analysis.

Authors:  Pauline Podeur; Julien Mancini; Jean Delgrande; Laure Santini; Sébastien Salas; Stéphanie Wong; Antoine Giovanni; Patrick Dessi; Justin Michel; Thomas Radulesco; Nicolas Fakhry
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.